Skip to main content
. 2023 Jan 18;15(3):600. doi: 10.3390/cancers15030600

Figure 2.

Figure 2

Forest plot of the efficacy of neoadjuvant immune checkpoint inhibitors in resectable hepatocellular carcinoma. (A) pCR, (B) MPR. pCR: pathological complete response; MPR: major pathological response [30,31,32,33,34,35,36,37,38].